Patience Needed On US Biosimilars, Says Samsung Bioepis’ Ko

Expectations For US Biosimilars ‘May Have Been Excessive’

 
• By Dave Wallace

In the first part of an exclusive interview with Generics Bulletin, Samsung Bioepis CEO Christopher Hansung Ko sets out his views on the US biosimilar market.

Hourglass
The US biosimilars market will take time to mature, Ko insists • Source: Shutterstock

More from Strategy

More from Business